134 related articles for article (PubMed ID: 11914202)
1. Periorbital dermatitis as a side effect of topical dorzolamide.
Delaney YM; Salmon JF; Mossa F; Gee B; Beehne K; Powell S
Br J Ophthalmol; 2002 Apr; 86(4):378-80. PubMed ID: 11914202
[TBL] [Abstract][Full Text] [Related]
2. Lichenoid drug eruption secondary to topical timolol and dorzolamide eye-drops.
Mullins RJ; Lones R; Dutta B
Australas J Dermatol; 2004 May; 45(2):151-2. PubMed ID: 15068470
[No Abstract] [Full Text] [Related]
3. [Postoperative behavior of intraocular pressure after posterior Nd:YAG laser capsulotomy--critical evaluation in preventive administration of local carbonic anhydrase II inhibitor dorzolamide hydrochloride (Trusopt)].
Lachmann C; Jörg KM; Trinkmann R
Klin Monbl Augenheilkd; 1998 Dec; 213(6):326-30. PubMed ID: 10048009
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients.
Renieri G; Führer K; Scheithe K; Lorenz K; Pfeiffer N; Thieme H
J Ocul Pharmacol Ther; 2010 Dec; 26(6):597-603. PubMed ID: 20977366
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
[TBL] [Abstract][Full Text] [Related]
6. Erythema multiforme after use of topical dorzolamide.
Munshi V; Ahluwalia H
J Ocul Pharmacol Ther; 2008 Feb; 24(1):91-3. PubMed ID: 18370879
[TBL] [Abstract][Full Text] [Related]
7. Allergic contact dermatitis due to dorzolamide eyedrops.
Mitsuyama S; Abe F; Higuchi T
Contact Dermatitis; 2021 Jan; 84(1):58-59. PubMed ID: 32700819
[No Abstract] [Full Text] [Related]
8. Irreversible corneal decompensation in patients treated with topical dorzolamide.
Konowal A; Morrison JC; Brown SV; Cooke DL; Maguire LJ; Verdier DV; Fraunfelder FT; Dennis RF; Epstein RJ
Am J Ophthalmol; 1999 Apr; 127(4):403-6. PubMed ID: 10218692
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial assessing dorzolamide in patients with glaucoma who are younger than 6 years.
Ott EZ; Mills MD; Arango S; Getson AJ; Assaid CA; Adamsons IA
Arch Ophthalmol; 2005 Sep; 123(9):1177-86. PubMed ID: 16157797
[TBL] [Abstract][Full Text] [Related]
10. POSSIBLE EFFICACY OF TOPICAL DORZOLAMIDE IN THE TREATMENT OF PACLITAXEL-RELATED CYSTOID MACULAR EDEMA.
Dwivedi R; Tiroumal S
Retin Cases Brief Rep; 2018 Winter; 12(1):75-79. PubMed ID: 27749791
[TBL] [Abstract][Full Text] [Related]
11. Update in glaucoma: the new pharmacotherapies. Dorzolamide hydrochloride.
Gould LF
Can J Ophthalmol; 1998 Aug; 33(5):253-4; discussion 257-8. PubMed ID: 9740951
[No Abstract] [Full Text] [Related]
12. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group.
Hutzelmann J; Owens S; Shedden A; Adamsons I; Vargas E
Br J Ophthalmol; 1998 Nov; 82(11):1249-53. PubMed ID: 9924327
[TBL] [Abstract][Full Text] [Related]
13. Allergic contact dermatitis from timolol and dorzolamide eye drops.
Kalavala M; Statham BN
Contact Dermatitis; 2006 Jun; 54(6):345. PubMed ID: 16787459
[No Abstract] [Full Text] [Related]
14. Fixed topical combinations in glaucomatous patients and ocular discomfort.
Nebbioso M; Evangelista M; Librando A; Di Blasio D; Pescosolido N
Expert Opin Pharmacother; 2012 Sep; 13(13):1829-35. PubMed ID: 22770575
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for periorbital dermatitis in patients using dorzolamide/timolol eye drops.
Kim M; Jang H; Rho S
Sci Rep; 2021 Sep; 11(1):17896. PubMed ID: 34504268
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of dose escalation of dorzolamide used in combination with other topical antiglaucoma agents.
Araie M; Kitazawa Y; Azuma I; Shirato S; Hamanaka T; Tomita G; Origasa H
J Ocul Pharmacol Ther; 2003 Dec; 19(6):517-25. PubMed ID: 14733709
[TBL] [Abstract][Full Text] [Related]
17. Hypotony and choroidal effusion induced by topical timolol and dorzolamide in patients with previous glaucoma drainage device implantation.
Callahan C; Ayyala RS
Ophthalmic Surg Lasers Imaging; 2003; 34(6):467-9. PubMed ID: 14620750
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide.
Clineschmidt CM; Williams RD; Snyder E; Adamsons IA
Ophthalmology; 1999 Dec; 106(12 Suppl):17-24. PubMed ID: 10598693
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta-blocker in patients with glaucoma.
Tsukamoto H; Noma H; Matsuyama S; Ikeda H; Mishima HK
J Ocul Pharmacol Ther; 2005 Apr; 21(2):170-3. PubMed ID: 15857284
[TBL] [Abstract][Full Text] [Related]
20. Short-term effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata.
Wirtitsch MG; Findl O; Kiss B; Petternel V; Heinzl H; Drexler W
Arch Ophthalmol; 2003 May; 121(5):621-5. PubMed ID: 12742838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
